Chardan analyst Daniil Gataulin raised the firm’s price target on Zura Bio (ZURA) to $12 from $11 and keeps a Buy rating on the shares following the Q3 report. The firm says tibulizumab’s Phase 2b in systemic sclerosis is on track for a Q4 initiation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: